SCPHARMACEUTICALS INC. Selling, General and Administrative Expense
SCPHARMACEUTICALS INC. reported Selling, General and Administrative Expense of $21.23 million for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2025-08-07
- SCPHARMACEUTICALS INC. selling, general and administrative expense for the quarter ending 2025-06-30 was $21.23M, a 21.24% increase year-over-year.
- SCPHARMACEUTICALS INC. selling, general and administrative expense for the quarter ending 2025-03-31 was $21.41M, a 22.70% increase year-over-year.
- SCPHARMACEUTICALS INC. selling, general and administrative expense for the quarter ending 2024-12-31 was $21.37M, a 31.60% increase year-over-year.
- SCPHARMACEUTICALS INC. selling, general and administrative expense for the quarter ending 2024-09-30 was $21.32M, a 50.83% increase year-over-year.
- SCPHARMACEUTICALS INC. selling, general and administrative expense for fiscal 2024 was $77.65M, a 45.49% increase from fiscal 2023.
- SCPHARMACEUTICALS INC. selling, general and administrative expense for fiscal 2023 was $53.37M, a 158.77% increase from fiscal 2022.
- SCPHARMACEUTICALS INC. selling, general and administrative expense for fiscal 2022 was $20.62M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2025-06-30 | $21.23M 10-Q · filed 2025-08-07 | $42.63M 10-Q · filed 2025-08-07 | $64.01M derived: sum of 3 quarters · filed 2025-08-07 | $85.33M derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | $21.41M 10-Q · filed 2025-05-14 | $42.78M derived: sum of 2 quarters · filed 2025-05-14 | $64.10M derived: sum of 3 quarters · filed 2025-05-14 | $81.61M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-12-31 | $21.37M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $42.69M derived: sum of 2 quarters · filed 2025-03-19 | $60.20M derived: sum of 3 quarters · filed 2025-08-07 | $77.65M 10-K · filed 2025-03-19 |
| 2024-09-30 | $21.32M 10-Q · filed 2024-11-13 | $38.83M derived: sum of 2 quarters · filed 2025-08-07 | $56.27M 10-Q · filed 2024-11-13 | $72.52M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-06-30 | $17.51M 10-Q · filed 2025-08-07 | $34.95M 10-Q · filed 2025-08-07 | $51.20M derived: sum of 3 quarters · filed 2025-08-07 | $65.33M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $17.45M 10-Q · filed 2025-05-14 | $33.69M derived: sum of 2 quarters · filed 2025-05-14 | $47.82M derived: sum of 3 quarters · filed 2025-05-14 | $59.92M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $16.24M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $30.38M derived: sum of 2 quarters · filed 2025-03-19 | $42.47M derived: sum of 3 quarters · filed 2025-03-19 | $53.37M 10-K · filed 2025-03-19 |
| 2023-09-30 | $14.13M 10-Q · filed 2024-11-13 | $26.23M derived: sum of 2 quarters · filed 2024-11-13 | $37.13M 10-Q · filed 2024-11-13 | $44.30M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $12.10M 10-Q · filed 2024-08-14 | $22.99M 10-Q · filed 2024-08-14 | $30.17M derived: sum of 3 quarters · filed 2024-08-14 | $36.45M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $10.90M 10-Q · filed 2024-05-14 | $18.07M derived: sum of 2 quarters · filed 2024-05-14 | $24.35M derived: sum of 3 quarters · filed 2024-05-14 | $28.63M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $7.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $13.45M derived: sum of 2 quarters · filed 2024-03-13 | $17.73M derived: sum of 3 quarters · filed 2024-03-13 | $20.62M 10-K · filed 2024-03-13 |
| 2022-09-30 | $6.28M 10-Q · filed 2023-11-08 | $10.56M derived: sum of 2 quarters · filed 2023-11-08 | $13.45M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $4.28M 10-Q · filed 2023-08-10 | $7.17M 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $2.89M 10-Q · filed 2023-05-10 |